Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method for the synthesis of clofarabine

A clofarabine and compound technology, applied in the field of α-N9 stereoisomers

Inactive Publication Date: 2016-12-21
SYNBIAS PHARMA
View PDF7 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In particular, there is a need for synthetic protocols that result in high yields of product and do not involve the formation of undesired stereoisomers

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for the synthesis of clofarabine
  • Method for the synthesis of clofarabine
  • Method for the synthesis of clofarabine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1a

[0068] Example 1a: Preparation of 2-chloroadenosine(III) from 2-chloroadenine and uridine

[0069] At 58-61°C, mix 400g uridine and 150g KH with stirring 2 PO 4 Dissolved in a mixture of water (52L) and DMSO (1.8L). To the resulting solution was added a first batch (0.75 L) of a solution prepared from 2-chloroadenine (85 g), water (7 L) and KOH (120 g). The pH of the resulting mixture was adjusted to 7.1-7.2 with aqueous KOH. At 58-61°C, a solution of uridine phosphorylase and purine nucleoside phosphorylase was added with stirring. The remaining second batch of 2-chloroadenine solution was sequentially added to the reaction mixture with stirring at 58-61°C over a period of 3 hours, maintaining the pH in the range 7.1-7.2 with aqueous HCl. Then, the reaction mixture was stirred at 58-61 °C for 1 hour, and NaOH was added to adjust the pH to 11.

[0070] Purification of the resulting solution containing 2-chloroadenosine by preparative chromatography followed by isolation...

Embodiment 1b

[0071] Example 1b: Preparation of 2-chloroadenosine(III) from 2-chloroadenine and guanine

[0072] At 58-61°C, mix 229g guanine and 75g KH with stirring 2 PO 4 Dissolved in a mixture of water (52L) and DMSO (1.8L). To the resulting solution was added a first batch (0.75 L) of a solution prepared from 2-chloroadenine (42 g), water (7 L) and KOH (60 g). The pH of the resulting mixture was adjusted to 7.1-7.2 with aqueous KOH. The solution of purine nucleoside phosphorylase was added to the reaction mixture with stirring at 58-61°C. The remaining second batch of 2-chloroadenine solution was sequentially added to the reaction mixture with stirring at 58-61°C over a period of 3 hours, maintaining the pH in the range 7.1-7.2 with aqueous HCl. Then, the reaction mixture was stirred at 58-61 °C for 1 hour, and NaOH was added to adjust the pH to 11.

[0073] The resulting solution containing 2-chloroadenosine was purified by low pressure reverse phase column chromatography follo...

Embodiment 2

[0074] Example 2: Benzoylation of 2-chloroadenosine

[0075] A solution of 2-chloroadenosine (750 g) in pyridine (7.5 L) was cooled to -5-0°C. Then, a solution of benzoyl chloride (720 g) in acetonitrile (1440 mL) was slowly added to the reaction mixture with stirring and cooling. Therefore, the internal temperature of the reaction mixture should not be higher than 5°C. The mixture was incubated for 30 min under the same conditions. Thereafter, the solvent was evaporated under reduced pressure at a temperature of 60°C. The residue was dissolved in CH 2 Cl 2 in, and sequentially with 1M H 2 SO 4 Aqueous solution, saturated NaHCO 3 Aqueous solution and water wash. The organic phase was evaporated under reduced pressure to obtain 2-chloro-9-(2',5'-di-O-benzoyl-β-D-ribofuranosyl)-adenine and 2-chloro-9 -(3',5'-di-O-benzoyl-β-D-ribofuranosyl)-adenine mixture (together about 65% by HPLC), and 2',3', 5'-Tri-O-benzoyl-2-chloroadenosine (about 30% by HPLC).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Method for the production of the anticancer nucleoside clofarabine in high yield, the method comprising the preparation of 2- chloroadenosine by enzymatic transglycosylation between 2- chloroadenine and nucleosides, benzoylation, isomerization, sulfonate ester formation, fluorination, and deprotection.

Description

technical field [0001] The present invention relates to a process for the production of clofarabine in high yield without formation of the undesired α-N9 stereoisomer. Background technique [0002] Clofarabine (systematic IUPAC name: 5-(6-amino-2-chloro-purin-9-yl)-4-fluoro-2-(hydroxy-methyl)oxolan-3-ol) is a A purine nucleotide antimetabolite useful in the treatment of various types of leukemia, especially acute lymphoblastic leukemia. [0003] Currently, several methods for the production of clofarabine are established in the art. Synthetic routes are typically based on coupling reactions between purine derivatives and arabinofuranosyl fragments. According to the method of fluorine atom introduction, these synthetic schemes can be divided into two groups: (i) the method of including fluorine atom in the ribofuranose moiety and introducing it into the molecule in the coupling step; (ii) after the coupling step , a method for the introduction of fluorine atoms by chemical...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12P19/40C07H19/173C07H1/00
CPCC07H1/00C07H19/173C12P19/40C12Y204/02001Y02P20/55C07H19/16A61P35/02C07H19/19
Inventor A·扎布德金V·马特维延科I·马特维延科V·瑟皮琴科
Owner SYNBIAS PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com